Verve Therapeutics, Inc.
VERV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.62 | -0.35 | -0.09 |
| FCF Yield | -33.78% | -17.75% | -12.97% | -4.60% |
| EV / EBITDA | -1.69 | -3.51 | -6.21 | -20.18 |
| Quality | ||||
| ROIC | -36.63% | -30.78% | -24.81% | -23.46% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.75 | 0.78 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | 155.39% | – | – | – |
| Free Cash Flow Growth | -1.63% | -17.16% | -64.84% | -112.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.60 | 0.21 | 0.73 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 36.75 | 183.06 | 190.30 | -764.91 |